Analysis of two datasets of mCRPC patients showed that BCL2 expression could potentially predict treatment responses in prostate cancer patients, as in patients with the history of taxane treatment, higher BCL2 levels correlated with an elevated prostate specific antigen (PSA) level, which is the indicator of prostate cancer biochemical recurrence 64. The gene discussed is KLK3; the disease is prostate carcinoma.